BioCentury
ARTICLE | Finance

Project management

Anemia play Akebia spins out newco Aerpio, both based on programs from P&G

January 9, 2012 8:00 AM UTC

Akebia Therapeutics Inc. has decided the best way to manage its diverse clinical-stage assets is to spin out a newco - Aerpio Therapeutics Inc.Akebia will focus on anemia, while Aerpio will focus on diabetic eye disease.

"As the pipeline matured, it made sense to and split them out," because the clinical-stage molecules target very different diseases, said Joseph Gardner, who is president and CEO of both companies...